Table 1.
Summary of study characteristics.
| Authors, Year (Reference Number) |
Country | Study Design | P/D Approach | Patients, n | Female, n (%) | Mean Age (Range) | Stage | NOS | Neoadjuvant/Adjuvant | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPP | P/D | EPP | P/D | EPP | P/D | |||||||
| Bovolato et al., 2014 [16] | Italy | R | P/D | 301 | 202 | 76 (25.3) | 53 (26.2) | 58.7 (33–78) | 62.5 (30–87) |
I: 9.5%; II: 27.6%; ≥III: 19%; ND: 43.7% (ND) |
6 | adjuvant CT RT |
| de Vries et al., 2003 [17] | South Africa |
R | P/D | 17 | 29 | – | – | – | – | I–III ** | 5 | adjuvant CT RT |
| Flores et al., 2008 [18] | USA | R | Extended P/D | 385 | 278 | 69 (18) |
58 (21) |
60 | 63 | I: 2%; II: 95%; III: 24%; IV: 16%; ND: 48% *** | 7 | adjuvant CT RT |
| Kai et al., 2019 [19] | Japan | R | Extended P/D | 29 | 15 | 0 (0) |
0 (0) |
64 (42–73) |
66 (48–72) |
I–IV * | 6 | neoadjuvant + adjuvant |
| Kanayama et al., 2022 [20] | Singapore | R | Extended P/D | 18 | 22 | 1 (5.6) |
3 (13.6) |
64.0 (51–77) |
69.5 (54–82) |
IA–IIIB * | 6 | adjuvant |
| Kostron et al., 2017 [21] | Switzerland | R PSM |
P/D and extended P/D | 141 | 26 | 16 (11) |
1 (4) |
61 (36–73) |
66 (34–77) |
I–IV * | 7 | neoadjuvant CT |
| Lang-Lazdunski et al., 2012 [22] | UK | P | P/D and extended P/D | 22 | 54 | 2 (8.1) |
7 (13) |
62 (52–68) |
62.5 (45–74) |
I–IV * | 6 | neoadjuvant + adjuvant |
| Luckraz et al., 2009 [23] | UK | R | P/D | 49 | 90 | 0 (0) |
4 (12) |
57.8 (12.6) | 63.5 (9.1) |
I–III ** | 5 | neoadjuvant + adjuvant |
| Okada et al., 2008 [24] | Japan | R | Extended P/D | 31 | 34 | 4 (13) |
3 (9) |
60 (35–72) |
60 (37–78) |
I–IV * | 6 | neoadjuvant + adjuvant |
| Rena et al., 2012 [25] | Italy | R | P/D | 40 | 37 | 29 (27) |
6 (32) |
56 ± 11 ° | 58.5 ± 9.5 ° | I, II (ND) | 6 | neoadjuvant + adjuvant |
| Sharkey et al., 2016 [26] | UK, Italy | R | Extended P/D | 133 | 229 | 19 (14) |
33 (14) |
57 (14–70) |
65 (42–81) |
I: 4%; II: 14%; III: 57%; IV: 25% * | 6 | neoadjuvant + adjuvant |
| Verma et al., 2017 [27] | USA | R | Extended P/D | 271 | 1036 | 60 (22) |
217 (21) |
65 (58–71) |
69 (62–76) |
I–IV (ND) | 7 | adjuvant CT RT |
| Zhou et al., 2021 [28] | USA | R PSM |
ND | 187 | 95 | 32 (17.1) | 24 (26.3) | 61 (56–67) |
65 (61–71) |
I–III (ND) | 6 | adjuvant RT |
EPP: extrapleural pneumonectomy; P/D: pleurectomy-decortication; NOS: Newcastle–Ottawa Quality Assessment Scale, number of stars; R: retrospective study; P: prospective study; PSM: propensity score matching; ND: non-defined; ° standard deviation; * IMIG 8th edition; ** Butchart and Brigham staging systems; *** AJCC Cancer Staging Handbook 6th edition.